[Relugolix : the first oral GnRH receptor antagonist for the treatment of advanced hormone-sensitive prostate cancer]
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性，不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接: https://pubmed.ncbi.nlm.nih.gov/41987547
其他信息:
PMID: 41987547
作者: Juline Verjans; David Waltregny; François Triffaux; Juline Verjans; Juline Verjans; ...
摘要: Relugolix is a recently introduced oral GnRH («Gonadotropin-Releasing Hormone») antagonist for the management of advanced hormone-sensitive prostate cancer. Unlike GnRH agonists, it directly and rapidly suppresses LH and FSH secretion without inducing an initial testosterone surge («flare up effect»), thereby avoiding transient clinical symptom exacerbation. The phase III HERO trial demonstrated its superiority over leuprolide, showing a faster and deeper testosterone suppression along with sign...
